榎木 裕紀 (エノキ ユウキ)

Enoki, Yuki

写真a

所属(所属キャンパス)

薬学部 薬学科 薬効解析学講座 (芝共立)

職名

助教

 
 

著書 【 表示 / 非表示

  • 調剤と情報-高齢者の低栄養と薬-

    榎木 裕紀松元 一明, じほう, 2018年10月

    担当範囲: 高齢者が低栄養になるとどうなる?-体内動態の変化と服薬上のリスク-

  • 新薬展望2018

    松元 一明榎木 裕紀, 医薬ジャーナル, 2018年02月

    担当範囲: 抗菌薬

論文 【 表示 / 非表示

  • Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research.

    榎木 裕紀

    Journal of pharmacy and pharmacology 2018年12月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  2042-7158

  • Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials

    榎木 裕紀

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  24 ( 11 ) 907 - 914 2018年12月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  1341-321X

     概要を見る

    © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases At present, vancomycin (VCM) and metronidazole (MNZ) are used for the first-line standard treatment of Clostridioides difficile infection (CDI). However, their differential use has not been sufficiently investigated. In this study, a meta-analysis on differences in the efficacy for CDI between VCM and MNZ was performed. Reports of randomized controlled studies using VCM or MNZ to treat CDI were surveyed. Meta-analysis was performed using the Mantel-Haenszel method and random-effects model, and the risk ratio and 95% confidence interval were calculated. Excluding overlapping reports, 1043 reports were extracted and 5 randomized controlled studies were extracted. There was no difference in therapeutic effects for CDI between VCM and MNZ (RR = 1.08, 95% CI (0.99–1.17), p = 0.09, I2 = 37%). On subgroup analysis by the severity, there was no difference in the clinical effects for CDI between VCM and MNZ in non-severe cases (risk ratio: 1.09, 95% confidence interval: 1.00–1.19, p = 0.06), but the clinical effects of VCM were significantly higher than those of MNZ in severe cases (risk ratio: 1.19, 95% confidence interval: 1.02–1.39, p = 0.03). No significant difference was noted in the recurrence rate, incidence of adverse event, time to exhibit therapeutic effects, or judgment of the bacteriological effects. As the therapeutic effects of VCM were superior in severe CDI cases, VCM should be considered first in severe cases.

  • Stability of benzylpenicillin potassium and ampicillin in an elastomeric infusion pump

    榎木 裕紀

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  24 ( 10 ) 856 - 859 2018年10月

    研究論文(学術雑誌),  ISSN  1341-321X

     概要を見る

    © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Some infectious diseases, such as infective endocarditis, osteomyelitis, and abscesses, require treatment with long-term intravenous antimicrobial treatment. Therefore, the patient is required to stay in the hospital to receive therapy, which lowers their quality of life. Establishing an outpatient parenteral antimicrobial therapy (OPAT) by continuous infusion pump is desired in Japan to overcome these issues. However, the 24-h stability of antimicrobial agents dissolved in infusion solutions is unclear. Thus, we investigated the stability of antimicrobial agents in five different infusion solutions in a clinical setting. Benzylpenicillin potassium (PCG) and ampicillin (ABPC) were dissolved separately in five different infusion solutions and kept at 25 or 31.1 °C for 24 h. The residual ratios were determined by high-performance liquid chromatography (HPLC). Dissolved PCG in acetate ringer solution remained stable for 24 h at temperatures of 25 and 31.1 °C (101.7 ± 1.4% and 92.9 ± 1.3%, respectively). In addition, the PCG solution did not adsorb onto the elastomeric infusion pump after 24 h at 31.1 °C. PCG dissolved in acetate ringer solution was also stable for 10 days after being kept in an elastomeric infusion pump at 4 °C (99.7 ± 0.5%). ABPC was unstable in all of the tested infusion solutions and temperatures. Based on our results, PCG in acetate ringer solution can be used in OPAT with continuous infusion pumps.

  • Development of kupffer cell targeting type-i interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions

    榎木 裕紀

    Drug Delivery (Drug Delivery)  25 ( 1 ) 1067 - 1077 2018年04月

    研究論文(学術雑誌),  ISSN  1071-7544

     概要を見る

    © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Because of its multifaceted anti-inflammatory and immunomodulatory effects, delivering type-I interferon to Kupffer cells has the potential to function as a novel type of therapy for the treatment of various types of hepatitis. We report herein on the preparation of a Kupffer cell targeting type-I interferon, an albumin-IFNα2b fusion protein that contains highly mannosylated N-linked oligosaccharide chains, Man-HSA(D494N)-IFNα2b, attached by combining albumin fusion technology and site-directed mutagenesis. The presence of this unique oligosaccharide permits the protein to be efficiently, rapidly and preferentially distributed to Kupffer cells. Likewise IFNα2b, Man-HSA(D494N)-IFNα2b caused a significant induction in the mRNA levels of IL-10, IL-1Ra, PD-L1 in RAW264.7 cells and mouse isolated Kupffer cells, and these inductions were largely inhibited by blocking the interferon receptor. These data indicate that Man-HSA(D494N)-IFNα2b retained the biological activities of type-I interferon. Man-HSA(D494N)-IFNα2b significantly inhibited liver injury in Concanavalin A (Con-A)-induced hepatitis model mice, and consequently improved their survival rate. Moreover, the post-administration of Man-HSA(D494N)-IFNα2b at 2 h after the Con-A challenge also exerted hepato-protective effects. In conclusion, this proof-of-concept study demonstrates the therapeutic effectiveness and utility of Kupffer cell targeting type-I interferon against hepatitis via its anti-inflammatory and immunomodulatory actions.

  • Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery

    Ichimizu S., Watanabe H., Maeda H., Hamasaki K., Nakamura Y., Chuang V., Kinoshita R., Nishida K., Tanaka R., Enoki Y., Ishima Y., Kuniyasu A., Kobashigawa Y., Morioka H., Futaki S., Otagiri M., Maruyama T.

    Journal of Controlled Release (Journal of Controlled Release)  277   23 - 34 2018年03月

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  1873-4995

     概要を見る

    © 2018 Human serum albumin (HSA) is a superior carrier for delivering extracellular drugs. However, the development of a cell-penetrating HSA remains a great challenge due to its low membrane permeability. We report herein on the design of a series of palmitoyl-poly-arginine peptides (CPPs) and an evaluation of their cell-penetrating effects after forming a complex with HSA for use in intracellular drug delivery. The palmitoyl CPPs forms a stable complex with HSA by anchoring itself to the high affinity palmitate binding sites of HSA. Among the CPPs evaluated, a cyclic polypeptide composed of D-dodecaarginines, palmitoyl-cyclic-(D-Arg) 12 was the most effective for facilitating the cellular uptake of HSA by HeLa cells. Such a superior cell-penetrating capability is primarily mediated by macropinocytosis. The effect of the CPP on pharmacological activity was examined using three drugs loaded in HSA via three different methods: a) an HSA-paclitaxel complex, b) an HSA-doxorubicin covalent conjugate and c) an HSA-thioredoxin fusion protein. The results showed that cell-penetrating efficiency was increased with a corresponding and significant enhancement in pharmacological activity. In conclusion, palmitoyl-cyclic-(D-Arg) 12 /HSA is a versatile cell-penetrating drug delivery system with great potential for use as a nano-carrier for a wide diversity of pharmaceutical applications.

全件表示 >>

研究発表 【 表示 / 非表示

  • ダプトマイシンによりクレアチニンキナーゼが上昇した肥満患者

    榎木裕紀,山本理紗子,佐村優,田口和明,松元一明

    第67回日本化学療法学会総会 (東京) , 2019年05月, ポスター(一般), 日本化学療法学会

  • JADERを用いたClostridium difficile腸炎と偽膜性大腸炎の発現に関する要因解析

    榎木 裕紀

    第65回 日本化学療法学会 東日本支部総会 (東京ドームシティホテル) , 2018年10月, 口頭(一般), 日本化学療法学会

  • 外来静注抗菌薬療法(OPAT)導入に向けたペニシリンGカリウムおよびアンピシリンの各種輸液製剤溶解後の安定性に関する検討

    榎木 裕紀

    第66回日本化学療法学会総会 (岡山) , 2018年05月, ポスター(一般), 日本化学療法学会

  • 慢性腎臓病病態の骨格筋萎縮における尿毒素の関与と新規治療戦略に関する検討

    榎木 裕紀,渡邊 博志,荒毛 里歩,異島 優,松元 一明,小田切 優樹,丸山 徹

    第2回日本老年薬学会学術大会, 2018年05月, 口頭(一般)

  • 高用量シスプラチン療法による腎障害に対するマグネシウム製剤の予防効果の検討

    榎木 裕紀

    第25回医療薬学フォーラム, 2017年07月, ポスター(一般), 日本医療薬学会

競争的資金等の研究課題 【 表示 / 非表示

  • 筋作動因子-尿毒症物質クロストークを標的としたCKD誘発サルコペニアの治療戦略

    2018年04月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 榎木 裕紀, 若手研究, 補助金,  代表

 

担当授業科目 【 表示 / 非表示

  • 課題研究(薬効解析学)

    2019年度

  • 演習(薬効解析学)

    2019年度

  • 卒業研究A

    2019年度

  • 実務実習事前学習4

    2019年度

  • 実務実習事前学習1

    2019年度

全件表示 >>